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17 Abstract—Since brain ischemia is one of the leading causes
of adult disability and death, neuroprotection of the ische-
mic brain is of particular importance. Acute neuroprotective
strategies usually have the aim of suppressing glutamate
excitotoxicity and an excessive N-methyl-D-aspartate
(NMDA) receptor function. Clinically tolerated antagonists
should antagonize an excessive NMDA receptor function
without compromising the normal synaptic function.
Kynurenic acid (KYNA) an endogenous metabolite of the
tryptophan metabolism, may be an attractive neuroprotec-
tant in this regard. The manipulation of brain KYNA levels
was earlier found to effectively enhance the histopatholo-
gical outcome of experimental ischemic/hypoxic states.
The present investigation of the neuroprotective capacity
of L-kynurenine sulfate (L-KYNs) administered systemically
after reperfusion in a novel distal middle cerebral artery
occlusion (dMCAO) model of focal ischemia/reperfusion
revealed that in contrast with earlier results, treatment with
L-KYNs worsened the histopathological outcome of
dMCAO. This contradictory result indicates that post-ische-
mic treatmentwith L-KYNsmay be harmful. 2013Published
by Elsevier Ltd. on behalf of IBRO.
Key words: focal cerebral ischemia, neuroprotection, glycine
co-agonist site, NMDAR, MCAO model, kynurenines.
18
19INTRODUCTION
20As a result of the high energy demands of the central
21nervous system (CNS), a deprivation of oxygen and
22glucose leads in a short time to abnormal glutamatergic
23transmission. Malfunctioning of the ATP-dependent
24transporters results in a disturbance of ionic
25homeostasis, depolarization and the excessive release
26of glutamate from neural and glial stores in the
27extrasynaptic space. Acute or prolonged over-activation
28of N-methyl-D-aspartate receptors (NMDARs) allows the
29excessive entry of Ca2+, initiating glutamate
30excitotoxicity, the common core feature of many
31neuropsychiatric disorders, including stroke, epilepsy,
32Alzheimer’s disease and Huntington’s disease (Endres
33and Dirnagl, 2002; Moskowitz et al., 2010).
34Neuroprotective strategies usually have the aim of
35suppressing an excessive NMDAR function. Indeed, a
36number of NMDA antagonists have proven to be robust
37neuroprotectants in animal models of an ischemic/
38hypoxic (I/H) state, but many failed in clinical trials in
39consequence of their adverse side-effects (Ikonomidou
40and Turski, 2002; Muir, 2006).
41The destructive effect of NMDAR over-activity is in
42contrast with the phenomenon that synaptic NMDAR
43activity mediates the survival of several types of
44neurons (Hetman and Kharebava, 2006; Hardingham,
452009). It has been reported that neurodegeneration in
46the basal ganglia is exacerbated by NMDAR antagonists
47(Ikonomidou et al., 2000), that an NMDAR antagonist
48enhanced apoptotic cell loss in a head trauma model
49(Pohl et al., 1999), and that synaptic NMDAR activity
50boosts intrinsic antioxidant defenses (Papadia et al.,
512008). Furthermore, the targeting of ischemic brain
52areas by global NMDAR antagonism can confuse the
53functioning of brain areas unaffected by ischemic
54damage (Gunduz-Bruce, 2009). In this regard, a
55clinically tolerated neuroprotectant should antagonize
56the NMDAR function when it is excessive, but not later,
57without compromising the normal synaptic function.
58NMDAR activation requires the definite depolarization
59of the cell and the presence of both glutamate and the full
60co-agonists glycine or D-serine (Kussius and Popescu,
612009; Papouin et al., 2012). Furthermore, the glycine
62co-agonist site is not saturated under physiological
63conditions, but is in a hyperactive state (Li et al., 2009;
64Fuchs et al., 2012). Glycine-site antagonists may be
65attractive neuroprotectants in this respect.
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66 Kynurenic acid (KYNA) is an endogenous metabolite
67 of the tryptophan metabolism. It is produced from its
68 precursor L-kynurenine (KYN) by the enzyme
69 kynurenine-aminotransferase II (KATII), and discharged
70 from the astrocytes in the CNS (Swartz et al., 1990).
71 KYNA is a competitive antagonist at the glycine/D-serine
72 co-agonist site of the NMDAR. Furthermore, it plays a
73 versatile role in pathological states, including
74 inflammatory (Moroni et al., 2012), vascular (Sas et al.,
75 2003) and antioxidant (Lugo-Huitron et al.) processes.
76 Acting on the a7 nicotinic acetylcholine receptor, KYNA
77 also influences the excitability of neurons (Banerjee et
78 al.). A huge body of evidence indicates that
79 manipulation of the brain KYNA levels can effectively
80 ameliorate the histopathological outcome of
81 experimental I/H state (Stone, 2000; Wu et al., 2000;
82 Schwarcz and Pellicciari, 2002; Stone and Addae, 2002;
83 Vamos et al., 2009; Zadori et al., 2009). The
84 neuromodulatory properties of KYNA are now well-
85 established (Vecsei et al., 2012).
86 In the present study, we investigated whether
87 L-kynurenine sulfate (L-KYNs) administered after
88 reperfusion (in a dose, formerly proved to be
89 neuroprotective) diminishes the neuronal damage
90 triggered by short-term occlusion of the distal middle
91 cerebral artery (dMCA) in the rat cerebral
92 somatosensory cortex. This novel dMCA occlusion
93 (dMCAO) model was recently developed and
94 characterized from histological and electrophysiological
95 aspects in our research group (L. Knapp, manuscript
96 under review).
97 EXPERIMENTAL PROCEDURES
98 Animals
99 Male Wistar rats (n= 23) weighing 200–250 g were
100 used. The animals were kept under controlled laboratory
101 conditions with free access to food and water. The
102 experiments were carried out in accordance with the
103 protocol for animal care approved by both the
104 Hungarian Health Committee (1998) and the European
105 Communities Council Directive (86/609/EEC).
106 Surgical procedure
107 Experiments were carried out under Nembutal
108 anesthesia. The body temperature was maintained at
109 37 ± 0.5 C with a self-regulating heating pad and rectal
110 probe (Supertech TMP-5a). The animals were fixed in a
111 stereotaxic headholder (David Kopf Instr.) and the left
112 masticatory muscle was removed. The surface of the
113 temporal skull was cleaned and the brain was exposed
114 with a high-speed microdrill. The exposed cortical
115 surface involved the trunk and main branches of the
116 MCA. To induce ischemia, the MCA was carefully lifted
117 through 1200 lm with a Fisher microsurgery hook with
118 the aid of a micromanipulator, and occluded for 30 min.
119 To terminate the occlusion, the hook was carefully
120 removed, and restoration of the blood flow was
121 confirmed under an operating microscope. Finally, the
122 dura and the temporal muscle were replaced, the skin
123was closed with a silk suture and the wound was
124cleaned with iodine solution. All interventions were
125strictly synchronized in time, to make the effect of
126Nembutal on the experiment uniform.
127Electrophysiology
12860 s of electroencephalography (EEG) was recorded on
129the surface of the skull with a silver electrode (2 mm
130lateral to the sutura sagittalis and 3 mm behind the
131bregma), promptly before and in the 29th–30th min after
132dMCAO (sampling rate: 1024 Hz; gain: 1000) with
133Experimetria NeuroSys software (Experimetria Ltd.,
134Hungary).
135EEG power analysis was performed with the EEGLab
136toolbox (Delorme and Makeig, 2004) and custom-written
137MATLAB 7.1 (Mathworks, Natick, Massachusetts, USA)
138software.
139The range of frequency of interest was assigned to
1402–20 Hz and further analysis was performed within this
141range.
142Histology
143Tissue processing. For the histological study, 5 days
144after dMCAO, animals were anesthetized with an
145overdose of urethane and perfused transcardially with
146ice-cold phosphate buffer (PB, 0.1 M, pH 7.4) and 4%
147paraformaldehyde (dissolved in 0.1 M PB, pH 7.4). The
148brains were removed and postfixed overnight in
149paraformaldehyde. On the next day, 20-lm coronal
150sections were obtained with a vibratome (Leica VT1000
151S) between 0.5 and 4 mm behind the bregma (Paxinos
152et al., 1980). Two adjacent slices were collected in
153500-lm steps, one for double immunostaining and the
154other for Fluoro Jade-C staining. Fluorescent
155photomicrographs were obtained with an Olympus BX51
156microscope fitted with a DP70 digital imaging system.
157Fluoro Jade-C staining. Fluoro Jade-C (FJ-C) staining
158was performed with the literature protocol (Schmued
159et al., 2005) with some modification. The slices were
160mounted on gelatine-coated slides, then coverslipped
161with Fluoromount. FJ-C-positive (FJ-C+) cells were
162counted in the ispilateral cortex at 40 magnification.
163Automated counting of FJ-C+ cells was performed with
164custom-written software in MATLAB 7.1 (Mathworks,
165Natick, Massachusetts, USA). After automated threshold
166adjustment and noise reduction, 25–400-lm2
167fluorescent objects were accepted as cells and counted
168in binary images.
169Immunohistochemistry. Glial reaction was detected
170with an indirect immunohistochemical method. 20-lm-
171thick free-floating sections were washed in PB, and then
172incubated in 10% normal donkey serum (NDS). For the
173detection of activated microglia (mouse anti-CD11b,
174clone OX42, 1:1000, Millipore) and reactive astrocytes
175(rabbit anti-S100, 1:2000, DAKO), sections were
176exposed to the primary antibodies overnight at 4 C, and
177to the appropriate secondary antibodies for 2 h at room
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178 temperature. Primary and secondary antibodies were
179 diluted in 0.1 M PB containing 0.4% Triton-X100, 2%
180 NDS and 0.01 % sodium azide. The sections were
181 coverslipped with an aqueous mounting medium.
182 Drug administration
183 The rats were divided into two groups: L-KYNs-treated
184 animals (n= 11) received 300 mg/kg L-KYNs (dissolved
185 in 5% NaOH, pH 7.4) intraperitoneally, immediately after
186 reperfusion, while the control animals (n= 12) were
187 treated with the vehicle.
188 All chemicals were purchased from VWR Ltd.,
189 Hungary, and Sigma, St. Louis, MO, USA.
190 Statistical analysis
191 Electrophysiology. EEG power spectra filtered at
192 2–20 Hz were decomposed at 1-Hz intervals. The EEG
193 power of a given frequency was considered as an
194 individual case. Analysis was performed with General
195 Linear Model/Repeated measures (IBM SPSS Statistics
196 version 20).
197 Histology. Numbers of FJ-C+ cells were compared
198 with the General Linear Model. The effects of the
199 different rats were used as random effects and the
200 different treatments were used as fixed effects in the
201 mixed effect linear model (IBM SPSS Statistics version
202 20).
203 RESULTS
204 Electrophysiology
205 The EEG registered for 60 s filtered for 2–20 Hz revealed
206 a marked and characteristic change in EEG during
207 dMCAO (Fig. 1). The power values in each frequency
208 bin were submitted to separate repeated-measures
209 analysis of variance, with period and frequency as
210 within-subject factors. All effects with two or more
211 degrees of freedom were adjusted for violations of
212 sphericity according to the Greenhouse–Geisser
213 correction.
214The ischemic period significantly reduced the power of
215the signal as compared with the power of the EEG
216registered before ischemia (main effect of period:
217F(1,21) = 32.989, p< 0.0001, g2 = 0.61; Fig. 2, panel
218A, B). It was earlier observed that somatosensory-
219evoked responses disappear completely during dMCAO
220(L. Knapp, manuscript under review). Together, these
221data indicate, that the dMCAO in our model resulted in
222a clean-cut decay of activity in the somatosensory
223cortices, i.e. the animals underwent a 30-min I/H period.
224Histology
225After a 5-day survival period, definite FJ-C staining and
226astrocyte/microglial activation throughout the
227somatosensory cortices emerged in approximately half
228of the animals, ipsilateral to the dMCAO (6/12 of the
229saline-treated animals; 5/11 of the L-KYNs-treated
230animals). In the remaining animals, no FJ-C staining
231and no glial reaction were observed, i.e. complete
232staining negativity. Ipsilateral to the dMCAO, astrocyte
233activation was characterized by hypertrophic astrocytes
234with prominent, thick processes and small vacuoles in
235the cell bodies as compared with the contralateral cortex
236(Fig. 3, panel A and insert). The microglia also revealed
237the activated phenotype ipsilateral to the dMCAO.
238Enlarged somata and the loss of secondary and tertiary
239branching were characteristic (Fig 3, panel B and
240insert). The glial reaction was more prominent in the
241L-KYNs-treated group (visual observation). The FJ-C
242staining distribution was similar to that in the activated
243microglia (compare Fig. 3, panels B, C). The groups
244were compared quantitatively for FJ-C staining. The
245number of FJ-C+ neurons was significantly higher in
246the L-KYNs-treated group (Fig. 4, General Linear Model;
247p= 0.023).
248DISCUSSION
249Physiological glutamatergic transmission through
250NMDARs is essential in the brain, playing a key role in
251development and synaptic plasticity. Due to its high
252permeability for Ca2+, the NMDAR is linked to several
253cell-signaling pathways, and to learning and memory
254(Nakazawa et al., 2004; Zhang et al., 2007). In certain
255acute and chronic neuropsychiatric disorders, however,
256Ca2+ entry is the key mediator of glutamate
257excitotoxicity and the NMDAR is the primary source of a
258toxic Ca2+ influx (Stanika et al., 2012). NMDAR
259antagonism is therefore an obvious neuroprotective
260approach.
261The failure of numerous antagonists in clinical trials is
262due in part to the different roles of synaptic and
263extrasynaptic NMDARs during excitotoxic processes.
264The hypothesis that extrasynaptic NMDARs mediate cell
265death, while synaptic NMDARs may promote survival
266was recently discussed (Hardingham and Bading, 2010;
267Li and Ju, 2012). From this respect, the selective
268targeting of extrasynaptic receptors without interfering
269with the normal synaptic function will involve a great
270advance (Chen and Lipton, 2006).
Fig. 1. EEG recordings from a rat somatosensory cortex ipsilateral to
the dMCAO. 60-s EEG recordings during control (black) and ischemic
(red) periods are superimposed. The EEG filtered for 2–20 Hz
revealed a marked change during dMCAO. (For interpretation of
the references to color in this figure legend, the reader is referred to
the web version of this article.)
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271 It has been argued that systemically administered
272 L-KYNs is neuroprotective in different I/H states (Gigler
273 et al., 2007; Sas et al., 2008). In such experiments, the
274I/H model triggered massive excitotoxicity and a high-
275level, long-lasting glutamate spillover. On the other
276hand, pre-ischemic treatment was effective, since the
Fig. 2. (Panel A) EEG power decomposed at 1-Hz intervals. Lines demonstrate the EEG power of given frequencies during the control (line) and
ischemic (dashed line) period (mean ± S.E.M.). (Panel B) The EEG power decreased significantly during the ischemic period (Repeated measures:
F(1,21) = 32.989, p< 0.0001, g2 = 0.61; mean ± S.E.M.).
Fig. 3. Representative photomicrograph of the rat somatosensory cortex ipsilateral to the dMCAO after L-KYNs treatment. Double immunostaining
of reactive astrocytes and microglia from the same slice; FJ-C staining from the adjacent slice (100 magnification, scale bars = 500 lm).
Astrocyte activation was characterized by hypertrophic astrocytes with prominent, thick processes and small vacuoles in the cell bodies (panel A,
and insert). The microglia also revealed an activated phenotype, enlarged somata and the loss of secondary and tertiary branching (panel B, and
insert). A high number of FJ-C+ neurons were seen throughout the cortex (panel C). The FJ-C staining pattern closely followed the microglia
distribution (compare panels B and C).
Fig. 4. FJ-C+ cells counted in the rat somatosensory cortex ipsilateral to the dMCAO. The numbers of FJ-C+ cells were compared with the
General Linear Model, and plotted in a bar chart. The cell number was significantly higher in the L-KYNs-treated group (General Linear Model;
p= 0.023; mean ± S.E.M.).
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277 KYN/KYNA transition in the astrocytes is time-consuming
278 (Swartz et al., 1990).
279 However, in a recent study we showed that a KYNA
280 derivative significantly diminished hippocampal
281 neurodegeneration, even if administered at the time of
282 reperfusion (Gellert et al., 2011).
283 A relatively brief MCAO evokes clean-cut
284 neurodegeneration in only a fraction of the animals
285 (Memezawa et al., 1992; Aspey et al., 2000; Popp
286 et al., 2009). Similarly, in our experiment only half of the
287 animals exhibited neurodegeneration, irrespectively of
288 whether they received L-KYNs or saline treatment.
289 However, the amplitude of the evoked responses (L.
290 Knapp, manuscript under review) and the EEG power
291 decreased markedly during dMCAO, and it may be
292 therefore postulated, that the somatosensory cortices
293 were subjected to an I/H state. This indicates that
294 endogenous protective processes are able to withstand
295 a short I/H state in this cortical area.
296 Systemic treatment with L-KYNs in our experiment did
297 not alter the probability of occurrence of
298 neurodegeneration, but extended the damaged area,
299 the glial activation and the number of FJ-C+ cells in the
300 animals, which ignited cell-death pathways.
301 Around one-quarter of the extrasynaptic NMDARs in
302 adult hippocampal slices are perisynaptic (within 100 nm
303 of the postsynaptic density). Of the dendritically
304 localized extrasynaptic NMDARs, around one-third is
305 adjacent to glia-like processes (Petralia et al., 2010).
306 KYNA produced in the glia may therefore, antagonize
307 both synaptic and extrasynaptic NMDARs, influencing
308 pro-death or survival mechanisms, respectively.
309 The emergence of KYNA produced de novo from
310 systemically administered L-KYNs takes time that is
311 considerable from the aspect of an excitotoxic process
312 (Swartz et al., 1990). However, KYNA or KYNA analogs
313 can act quickly after administration. Furthermore, during
314 a brief I/H state the presence of excessive glutamate
315 and concomitant extrasynaptic NMDAR activation can
316 last for minutes (Benveniste et al., 1984; Ikonomidou
317 and Turski, 2002). The phenomenon that the KYNA
318 analog, but not L-KYNs, is neuroprotective when
319 administered after reperfusion may depend on the
320 intensity and duration of the I/H state, the concomitant
321 glutamate spillover, and the duration of the KYN-KYNA
322 turnover.
323 Another possible explanation would be that L-KYNs
324 administration led to the increased concentrations of
325 quinolinic acid (QUIN) and 3-hydroxykynurenine (3-HK),
326 neurotoxic components of the kynurenine pathway.
327 Several studies observed that increased brain KYNA
328 levels follow systemic administration of L-KYNs. Swartz
329 et al. found that striatal KYNA level increased gradually
330 as a result of L-KYNs administered systemically in
331 gradually increased doses. The main conclusion of this
332 study was that extracellular levels of KYNA can be
333 dramatically increased by pharmacologic manipulation
334 of precursor levels (Swartz et al., 1990).
335 In another study concerning the effect of systemically
336 administered L-KYNs on cortical spreading depression,
337 intraperitoneal injections of L-KYNs were found to
338increase cortical KYNA level about 40-fold in rats
339(Chauvel et al., 2012).
340Investigating the effect of systemically administered L-
341KYNs on sensory gating, Shepard and associates found
342that systemic administration of L-KYNs was not followed
343by an increase of the harmful L-KYN metabolite, QUIN
344(Shepard et al., 2003).
345Astrocytes do not contain kynurenine 3-hydroxylase
346and therefore cannot produce 3-HK, but are able to
347produce large amounts of KYN and KYNA, whereas
348microglial cells preferentially produce intermediates of
349the quinolinic branch of the KYN pathway. It has also
350been demonstrated that the other main source of QUIN
351is the macrophage, infiltrated during inflammatory
352processes (Guillemin et al., 2001; Wonodi and
353Schwarcz, 2010).
354In the main, the activation of the microglia increases
355extracellular levels of QUIN or other kynurenines that
356exacerbate neuronal damage (Schwarcz and Pellicciari,
3572002).
358In gerbils subjected to a period of cerebral ischemia,
35950-fold QUIN level increases were observed 7 days
360after the onset of ischemia (Heyes and Nowak, 1990).
361Finally, increased L-kynurenine influx from the blood
362exceeds the catabolic capacity of kynurenine 3-
363hydroxylase in microglia, promoting KYNA production in
364the astrocytes (Wonodi and Schwarcz, 2010).
365Microglia activation and the infiltration of the
366macrophages follow the ischemic insult with a certain
367delay. So we might reasonably conclude that the
368extension of the damaged area in our experiments is
369not the result of high 3-HK or QUIN levels originated
370from L-KYNs administered promptly after reperfusion.
371Extension of the neural damage is attributable to the
372disturbed NMDAR-mediated survival mechanisms.
373These data indicate that kynurenergic manipulation
374remains a potent strategy against excitotoxic cell death,
375but the excitotoxic state and treatment pattern should be
376well-tuned.
377CONCLUSION
378Suppression of excessive NMDA function has long been
379the focus of research aimed at neuroprotection after
380brain ischemia. However, robust NMDA antagonism is
381not acceptable from the clinical point of view, since
382normal synaptic NMDA function should not be inhibited,
383even in the ischemic brain. The endogenous KYNA
384acting at the glycine/D-serine co-agonist site of the
385NMDA receptors is a pharmacon that might potentially
386absolve this contradiction. Indeed, a huge body of
387evidence indicates that manipulation of the brain KYNA
388levels can effectively enhance the histopathological
389outcome of the experimental I/H state. However, the
390neuroprotective potential of L-KYNs administered after
391brief focal ischemia has not yet been tested;
392surprisingly, treatment with L-KYNs worsened the
393histopathological outcome in our experiments. This
394contradictory result indicates that post-ischemic
395treatment with L-KYNs may be harmful.
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